本研究针对多参数磁共振成像(mpMRI)诊断临床显著性前列腺癌(csPCa)阳性预测值较低、PSA密度(PSAd)最佳阈值存在争议的问题，通过回顾性分析2190例疑似前列腺癌患者数据，系统评估了前列腺体积和PI-RADS分类对PSAd诊断性能的影响。研究发现PI-RADS 1-2和PI-RADS 3患者的 ...

本研究针对重复前列腺活检中PI-RADS 3病变的诊断挑战，通过回顾性分析684例患者数据，发现PI-RADS 3是阴性活检的独立预测因子（OR 0.582），而PSA密度（PSAD）在PI-RADS 4-5病变中具有显著风险分层价值（62.4% vs 33.8%），在PI-RADS 3中则差异有限（20.7% vs 16.2%）。该研究为 ...

Men overestimate the risks for clinically significant prostate cancer based on prostate MRI PI-RADS findings, regardless of the context in which those risks are presented, suggesting that clinicians ...

PI-RADS version 2.1 demonstrated improved detection of clinically significant prostate cancer in the transition zone. For detecting clinically significant prostate cancer (csPCa), prostate imaging ...

Upgrade and downgrade rates from targeted biopsy to radical prostatectomy were not significantly different between patients whose MRI examinations were clinically interpreted using PI-RADS Version ...

Survival impact of initial local therapy selection for men under 60 with high risk prostate cancer. Prostate cancer (PCa) in 696 hypogonadal men with and without long-term testosterone therapy (TTh): ...

PSMA-based PET imaging in newly diagnosed, high-risk localized prostate cancer, a National Cancer Institute (NCI) Cancer Moonshot trial. This is an ASCO Meeting Abstract from the 2025 ASCO ...